在接受动脉内肿瘤治疗的患者中,基于基线MRI强化特征识别结直肠癌肝转移的分期标志物
回顾性纳入2001至2014年接受经动脉化疗栓塞或Y90经动脉放射性栓塞治疗的88例结直肠癌肝转移患者,在治疗前MRI上对最多3个优势病灶行半自动分割,计算三维全肝及肿瘤强化特征,评估其预测生存的价值。多因素分析显示强化肿瘤直径、总体肿瘤体积、强化肿瘤体积和强化肿瘤负荷均为独立预测因子,全肝强化指标及一维/非强化方法无独立预测价值。作者认为强化肿瘤体积和强化肿瘤负荷可能优于非强化及一维标志物。
要点
- 治疗前MRI上结直肠癌肝转移的肿瘤强化与动脉内治疗后生存强相关。
- 强化肿瘤体积(HR 2.3)和强化肿瘤负荷(HR 2.4)在多因素分析中为独立预测因子。
- 全肝强化指标(ELB、ELV)及一维/非强化方法不是独立预测因子。
核心结论
- 结直肠癌肝转移在基线MRI上的肿瘤强化与动脉内治疗后患者生存强相关,提示强化肿瘤体积和强化肿瘤负荷可能是优于非强化及一维标志物的预后指标。
研究设计与样本
- 回顾性研究纳入88例结直肠癌肝转移患者,于2001至2014年间接受经动脉化疗栓塞或Y90经动脉放射性栓塞治疗;在治疗前MRI上对最多3个优势病灶行半自动分割,计算总体肿瘤体积和全肝体积,并行定量三维分析计算强化肿瘤体积、强化肿瘤负荷(ETV/TLV)、强化肝体积和强化肝负荷(ELV/TLV),同时测量总体及强化肿瘤直径;采用改良Kaplan-Meier法确定各指标截断值,以Kaplan-Meier生存曲线及单因素、多因素Cox比例风险模型评估预测价值。
关键影像表现/征象
- 治疗前MRI上结直肠癌肝转移的肿瘤强化在三维定量分析中表现为可计算的强化肿瘤体积和强化肿瘤负荷。
- 全肝强化指标(强化肝负荷、强化肝体积)及一维/非强化方法均不是生存的独立预测因子。
诊断标准与关键数值
- 多因素分析中强化肿瘤直径HR 2.1(95%CI 1.3-3.4,p=0.004)。
- 多因素分析中总体肿瘤体积HR 1.7(95%CI 1.1-2.8,p=0.04)。
- 多因素分析中强化肿瘤体积HR 2.3(95%CI 1.4-3.9,p<0.001)。
- 多因素分析中强化肿瘤负荷HR 2.4(95%CI 1.4-4.0,p=0.001)。
临床应用与阅片要点
- 作者认为强化肿瘤体积和强化肿瘤负荷可能作为肝优势结直肠癌转移患者新型预后分期系统的基础。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine if three-dimensional whole liver and baseline tumor enhancement features on MRI can serve as staging biomarkers and help predict survival of patients with colorectal cancer liver metastases (CRCLM) more accurately than one-dimensional and non-enhancement-based features.
METHODS: This retrospective study included 88 patients with CRCLM, treated with transarterial chemoembolization or Y90 transarterial radioembolization between 2001 and 2014. Semi-automated segmentations of up to three dominant lesions were performed on pre-treatment MRI to calculate total tumor volume (TTV) and total liver volumes (TLV). Quantitative 3D analysis was performed to calculate enhancing tumor volume (ETV), enhancing tumor burden (ETB, calculated as ETV/TLV), enhancing liver volume (ELV), and enhancing liver burden (ELB, calculated as ELV/TLV). Overall and enhancing tumor diameters were also measured. A modified Kaplan-Meier method was used to determine appropriate cutoff values for each metric. The predictive value of each parameter was assessed by Kaplan-Meier survival curves and univariable and multivariable cox proportional hazard models.
RESULTS: All methods except whole liver (ELB, ELV) and one-dimensional/non-enhancement-based methods were independent predictors of survival. Multivariable analysis showed a HR of 2.1 (95% CI 1.3-3.4, p = 0.004) for enhancing tumor diameter, HR 1.7 (95% CI 1.1-2.8, p = 0.04) for TTV, HR 2.3 (95% CI 1.4-3.9, p < 0.001) for ETV, and HR 2.4 (95% CI 1.4-4.0, p = 0.001) for ETB.
CONCLUSIONS: Tumor enhancement of CRCLM on baseline MRI is strongly associated with patient survival after intra-arterial therapy, suggesting that enhancing tumor volume and enhancing tumor burden are better prognostic indicators than non-enhancement-based and one-dimensional-based markers.
KEY POINTS: • Tumor enhancement of colorectal cancer liver metastases on MRI prior to treatment with intra-arterial therapies is strongly associated with patient survival. • Three-dimensional, enhancement-based imaging biomarkers such as enhancing tumor volume and enhancing tumor burden may serve as the basis of a novel prognostic staging system for patients with liver-dominant colorectal cancer metastases.
引用
- Ghani MA, Fereydooni A, Chen E, et al. Identifying enhancement-based staging markers on baseline MRI in patients with colorectal cancer liver metastases undergoing intra-arterial tumor therapy. Eur Radiol. 2021. PMID: 34061209. doi:10.1007/s00330-021-08058-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。